logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (7)
  • CSV
  • BibTeX
  • EndNote
  • All Results (7)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Editorial

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Journal Article
|
Research
Journal Article
|
Letter

Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes

Campbell JR, Chan ED, Anderson LF, Bonnet M, Brode SK, 
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

et al.
2023-04-01 • International Journal of Tuberculosis and Lung Disease
2023-04-01 • International Journal of Tuberculosis and Lung Disease

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF,  et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...

MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM,  et al.
2020-02-01 • International Journal of Infectious Diseases
2020-02-01 • International Journal of Infectious Diseases
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at provid...

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A,  et al.
2020-03-17 • Lancet Respiratory Medicine
2020-03-17 • Lancet Respiratory Medicine

BACKGROUND

Tre...

Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes

Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Drug-resistant tuberculosis (TB) is an important public health problem in Latvia.

OBJECTIVE
To document trends, characteristics and treatment outcomes of registe...